<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-103" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Nebivolol</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Priyadarshni </surname>
            <given-names>Shivani</given-names>
          </name>
          <aff>Aventura Hospital and medical center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Curry</surname>
            <given-names>Bryan H.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shivani Priyadarshni declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bryan Curry declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>6</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-103.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">This&#x000a0;activity focuses on&#x000a0;nebivolol, a potent medication used to treat&#x000a0;hypertension.&#x000a0;A thorough discussion of&#x000a0;nebivolol&#x02019;s dual role as a vasodilator and cardioselective &#x003b2;-blocker underscores its versatility&#x000a0;when managing cardiovascular conditions. As a selective &#x003b2;-blocker targeting &#x003b2;-1 adrenergic receptors, nebivolol&#x02019;s mechanism of action&#x000a0;allows&#x000a0;modulation of cardiac function while sparing &#x003b2;-2 receptors in the lungs and smooth muscles. This cardioselective profile&#x000a0;makes nebivolol crucial&#x000a0;for managing hypertension and vascular disease. By&#x000a0;understanding&#x000a0;its pharmacological actions, indications, contraindications,&#x000a0;pharmacokinetics, and adverse event profiles, healthcare professionals gain the necessary knowledge to administer this medication effectively.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify&#x000a0;the mechanism of action of nebivolol.</p></list-item><list-item><p>Assess&#x000a0;the adverse&#x000a0;drug reactions of nebivolol.</p></list-item><list-item><p>Determine&#x000a0;the appropriate clinical monitoring&#x000a0;of&#x000a0;patients receiving nebivolol.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from&#x000a0;nebivolol pharmacotherapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=103&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=103">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-103.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Nebivolol is an FDA-approved medication used to treat hypertension.<xref ref-type="bibr" rid="article-103.r1">[1]</xref>&#x000a0;Beta-blockers are a class of agents used to treat multiple conditions, including&#x000a0;hypertension, angina, arrhythmias, anxiety, hyperthyroidism, migraine prevention, and prevention of essential tremors.<xref ref-type="bibr" rid="article-103.r2">[2]</xref><xref ref-type="bibr" rid="article-103.r3">[3]</xref>&#x000a0;The American College of Cardiology (ACC)/American Heart Association (AHA) guidelines advise against using &#x003b2;-blockers as the first-line treatment for hypertension and to reserve them for patients&#x000a0;with comorbidities such as ischemic heart disease.<xref ref-type="bibr" rid="article-103.r4">[4]</xref></p>
        <p>Beta-blockers fall into&#x000a0;2 categories based on whether they block &#x003b2;-1 receptors in cardiac muscles, &#x003b2;-2 receptors in the lungs and smooth muscles, or both. Beta-blockers are also classified as vasodilators&#x000a0;or non-vasodilators based on their vasodilatory capabilities. The FDA has also approved a fixed-dose combination of nebivolol and valsartan&#x000a0;for hypertension management.<xref ref-type="bibr" rid="article-103.r5">[5]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Nebivolol is approved by the U.S. Food and Drug Administration (FDA) for the treatment of hypertension. Clinicians should prioritize the use of medications such as &#x003b2;-blockers, ACE inhibitors, or ARBs for adults with a diagnosis of stable ischemic heart disease (SIHD)&#x000a0;or hypertension and a history of myocardial infarction or stable angina. Additionally, individuals who have experienced a myocardial infarction or acute coronary syndrome are advised to continue guideline-directed medical therapy (including &#x003b2;-blockers) for at least 3 years as part of their long-term hypertension management.<xref ref-type="bibr" rid="article-103.r4">[4]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>The 2021 European Society of Cardiology (ESC) Guidelines for Heart Failure suggest nebivolol as a treatment option in combination with first-line therapies.<xref ref-type="bibr" rid="article-103.r6">[6]</xref> Nebivolol can also&#x000a0;help manage&#x000a0;microvascular angina.<xref ref-type="bibr" rid="article-103.r7">[7]</xref>&#x000a0;There is potential for nebivolol&#x000a0;in&#x000a0;managing&#x000a0;cancer therapy-related cardiac dysfunction (CTRCD), but further research is required.<xref ref-type="bibr" rid="article-103.r8">[8]</xref><xref ref-type="bibr" rid="article-103.r9">[9]</xref><xref ref-type="bibr" rid="article-103.r10">[10]</xref></p>
      </sec>
      <sec id="article-103.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Nebivolol is a &#x003b2;-1 adrenergic receptor antagonist that works&#x000a0;by blocking beta-1 receptors, making it&#x000a0;a cardioselective &#x003b2;-blocker. This drug also acts on the vascular endothelium by stimulating nitric oxide (NO) synthase, which induces NO-mediated vasodilation. Nebivolol stimulates NO synthase production from the endothelium via &#x003b2;-3 agonism, reducing systemic vascular resistance. Beta-blockers such as labetalol and carvedilol also have vasodilatory effects; however, their mechanism is via the blockade of &#x003b1;-adrenergic receptors. Patients with diabetes mellitus, erectile dysfunction, and vascular disease may have abnormal endothelial function, and nebivolol is more effective in these populations due to its NO-induced vasodilatory effect.<xref ref-type="bibr" rid="article-103.r11">[11]</xref><xref ref-type="bibr" rid="article-103.r12">[12]</xref><xref ref-type="bibr" rid="article-103.r13">[13]</xref>&#x000a0;</p>
        <p>Nebivolol is chemically composed of a racemic mixture of L-nebivolol and D-nebivolol. This medication is classified as&#x000a0;a third-generation &#x003b2;-1 adrenergic receptor antagonist and has the&#x000a0;strongest &#x003b2;-receptor affinity&#x000a0;of all &#x003b2;-blockers. This affinity explains its&#x000a0;excellent tolerability in patients with lung disease. Nebivolol is also unique&#x000a0;because of its &#x003b2;-1 vs. &#x003b2;-1 and &#x003b2;-2 selectivity. At low doses (&#x02264;10 mg) and in patients who are fast metabolizers, nebivolol is &#x003b2;-1 selective. However, nebivolol loses its selectivity and blocks &#x003b2;-1 and &#x003b2;-2 receptors at higher doses and in patients&#x000a0;who are&#x000a0;slower&#x000a0;metabolizers.<xref ref-type="bibr" rid="article-103.r14">[14]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Nebivolol reaches peak plasma concentration after 1.5&#x000a0;to 4 hours. Since food does not modify its pharmacokinetics, nebivolol tablets may be administered without regard to meals.</p>
        <p><bold>Distribution:</bold>&#x000a0;Nebivolol is 98 % protein-bound and binds primarily to albumin.</p>
        <p><bold>Metabolism:</bold>&#x000a0;Nebivolol is primarily metabolized in the liver via direct glucuronidation and secondarily through CYP2D6. The hydroxyl and glucuronide metabolites&#x000a0;are pharmacologically active. Nebivolol is metabolized by CYP2D6. Pharmacogenetic variations of this enzyme can affect various pharmacokinetics parameters; the active isomer (D-nebivolol) has a half-life of about 12 hours in&#x000a0;fast metabolizers of CYP2D6 and 19 hours in&#x000a0;slow metabolizers of CYP2D6. However,&#x000a0;these variations&#x000a0;are only mildly&#x000a0;relevant as the circulating hydroxyl and glucuronide metabolites also contribute to the &#x003b2;-blocking activity. The clinical efficacy and safety profiles of nebivolol are similar regardless of&#x000a0;slow or&#x000a0;fast metabolism status; no dose adjustment is necessary.</p>
        <p><bold>Elimination:</bold>&#x000a0;Nebivolol is excreted via&#x000a0;urine (35%) and&#x000a0;feces (44%); patients who are&#x000a0;slow metabolizers excrete 67% in urine and 13% in feces. Nebivolol&#x000a0;is excreted as oxidative metabolites or glucuronide conjugates.<xref ref-type="bibr" rid="article-103.r15">[15]</xref></p>
      </sec>
      <sec id="article-103.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths </bold>
</p>
        <p>Nebivolol is administered orally and&#x000a0;is not&#x000a0;available in intravenous form. Oral tablets are available as&#x000a0;nebivolol hydrochloride salt equivalent to 2.5, 5, 10, and 20 mg of nebivolol.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p><bold>Hypertension:&#x000a0;</bold>In a patient with hypertension, nebivolol dosing should be based on the patient's individual needs. The recommended starting dose for most patients is 5 mg once daily, which&#x000a0;can&#x000a0;be taken independently of meals. If further&#x000a0;blood pressure reduction is necessary, the dose can be titrated up at 2 to 4-week intervals based on the clinical response. The maximum dose is 40 mg once daily. Nebivolol is a CYP2D6 substrate; drug-drug interactions should be considered before prescribing nebivolol.&#x000a0;A recent review suggests that nebivolol&#x000a0;is also effective in African-American patients with hypertension, who demonstrate&#x000a0;decreased&#x000a0;responsiveness to &#x003b2;-blockers&#x000a0;compared to other ethnicities.<xref ref-type="bibr" rid="article-103.r16">[16]</xref></p>
        <p>Nebivolol&#x000a0;should never be&#x000a0;discontinued abruptly, and taper-off dosing&#x000a0;is recommended if the patient needs to stop using nebivolol. Rebound hypertension, tachycardia, exacerbation of cardiac arrhythmia, and hospitalization are reported when &#x003b2;-blockers are stopped abruptly.<xref ref-type="bibr" rid="article-103.r17">[17]</xref></p>
        <p>
<bold>Specific Patient Population</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>Per product labeling, the initial recommended dose is 2.5 mg orally once daily, which is titrated slowly (if needed) for patients with moderate hepatic impairment. No data is available on nebivolol use&#x000a0;for patients with severe hepatic impairment.&#x000a0;</p>
        <p><bold>Renal impairment: </bold>Per product labeling, the initial recommended dose for patients with severe renal impairment (CrCl &#x0003c;30 mL/min) is 2.5 mg orally once daily, titrated slowly if needed. There is no data available on nebivolol use&#x000a0;for patients on dialysis.</p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>Nebivolol&#x000a0;is a former&#x000a0;FDA pregnancy Category C&#x000a0;medicine.&#x000a0;If nebivolol is required&#x000a0;for a pregnant woman with a history of hypertension, then fetal monitoring is indicated.&#x000a0;The baby should be monitored for the first 48 hours post-delivery for possible&#x000a0;hypoglycemia, bradycardia, and respiratory depression.<xref ref-type="bibr" rid="article-103.r18">[18]</xref><xref ref-type="bibr" rid="article-103.r19">[19]</xref>&#x000a0;The American College of Gynecology &#x00026; Obstetrics (ACOG) recommends treatment with labetalol for hypertensive disorders of pregnancy.<xref ref-type="bibr" rid="article-103.r20">[20]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>There is no information on using nebivolol&#x000a0;for&#x000a0;women who are breastfeeding. The risk of &#x003b2;-blockers causing bradycardia in breastfed infants should be considered, and an alternate drug with safer profiles should be administered.<xref ref-type="bibr" rid="article-103.r19">[19]</xref></p>
        <p><bold>Pediatric patients:&#x000a0;</bold>The safety and efficacy of nebivolol&#x000a0;for pediatric patients have not been verified.</p>
        <p><bold>Older patients:&#x000a0;</bold>The SENIORS study assessed nebivolol's effects in heart failure patients aged 70 or older, regardless of ejection fraction. Nebivolol reduced combined mortality and cardiovascular admissions compared to placebo, independent of age, gender, or ejection fraction. In conclusion, nebivolol was effective and well-tolerated in older&#x000a0;patients with heart failure.<xref ref-type="bibr" rid="article-103.r21">[21]</xref></p>
      </sec>
      <sec id="article-103.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Nebivolol's reported adverse effects typically involve the central nervous system (CNS). Headache is the most commonly reported&#x000a0;adverse&#x000a0;effect (6% to 9%).<xref ref-type="bibr" rid="article-103.r22">[22]</xref><xref ref-type="bibr" rid="article-103.r23">[23]</xref></p>
        <p>Other common&#x000a0;adverse effects include:<xref ref-type="bibr" rid="article-103.r24">[24]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Fatigue (Dose-dependent)</p>
          </list-item>
          <list-item>
            <p>Dizziness</p>
          </list-item>
          <list-item>
            <p>Rhinitis</p>
          </list-item>
          <list-item>
            <p>Insomnia</p>
          </list-item>
          <list-item>
            <p>Asthenia</p>
          </list-item>
          <list-item>
            <p>Hyperuricemia</p>
          </list-item>
          <list-item>
            <p>Paresthesias</p>
          </list-item>
          <list-item>
            <p>Weakness</p>
          </list-item>
          <list-item>
            <p>Some less observed adverse&#x000a0;drug reactions are skin rash&#x000a0;and&#x000a0;gastrointestinal&#x000a0;adverse effects such as diarrhea, nausea, and abdominal pain.</p>
          </list-item>
        </list>
        <p>Less common&#x000a0;adverse effects&#x000a0;documented in case reports and post-marketing reports include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute pulmonary edema</p>
          </list-item>
          <list-item>
            <p>Acute kidney injury</p>
          </list-item>
          <list-item>
            <p>Second and third-degree atrioventricular (AV) block</p>
          </list-item>
          <list-item>
            <p>Bronchospasm</p>
          </list-item>
          <list-item>
            <p>Angioedema</p>
          </list-item>
          <list-item>
            <p>Hypersensitivity reaction</p>
          </list-item>
          <list-item>
            <p>Claudication</p>
          </list-item>
          <list-item>
            <p>Drug-induced liver injury:&#x000a0;elevated serum ALT, AST, and serum bilirubin</p>
          </list-item>
          <list-item>
            <p>Thrombocytopenia</p>
          </list-item>
          <list-item>
            <p>Raynaud phenomenon</p>
          </list-item>
          <list-item>
            <p>Somnolence</p>
          </list-item>
          <list-item>
            <p>Syncope</p>
          </list-item>
          <list-item>
            <p>Erectile dysfunction (less common than for conventional &#x003b2;-blockers)&#x000a0;<xref ref-type="bibr" rid="article-103.r16">[16]</xref><xref ref-type="bibr" rid="article-103.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>Psoriasis&#x000a0;<xref ref-type="bibr" rid="article-103.r26">[26]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>The CYP2D6 system metabolizes nebivolol. The dose may need to be reduced when giving nebivolol and CYP2D6 inhibitors. Nebivolol's potential drug-drug interactions include medication classes that are either substrate or inhibitors/inducers of CYP2D6.<xref ref-type="bibr" rid="article-103.r16">[16]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>CYP2D6 substrates: antiarrhythmics (class 1), 5-HT3 receptor antagonists, antidepressants, analgesics (opioids), protease inhibitors (ritonavir),&#x000a0;antipsychotics, cholinesterase inhibitors</p>
          </list-item>
          <list-item>
            <p>CYP2D6 inhibitors: antiarrhythmics (class 3), antihistamines, antipsychotics, protease inhibitors (eg, ritonavir, tipranavir), antimalarials, H2 receptor antagonists</p>
          </list-item>
          <list-item>
            <p>CYP2D6 inducers: antiseizure medications</p>
          </list-item>
          <list-item>
            <p>When &#x003b2;-blockers are administered with non-dihydropyridine calcium channel blockers (eg, verapamil, diltiazem), they may cause significant negative inotropic and chronotropic effects. EKG and blood pressure monitoring are recommended when&#x000a0;these agents are administered together.<xref ref-type="bibr" rid="article-103.r27">[27]</xref></p>
          </list-item>
          <list-item>
            <p>Rivastigmine administered with &#x003b2;-blockers can&#x000a0;cause bradycardia and possible syncope.<xref ref-type="bibr" rid="article-103.r3">[3]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-103.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Nebivolol should be used cautiously with a history of severe anaphylaxis to various allergens. Repeat challenges among patients taking &#x003b2;-blockers may cause increased sensitivity to severe anaphylaxis. Treating anaphylaxis in patients&#x000a0;using &#x003b2;-blockers may not be effective and promote undesirable effects.<xref ref-type="bibr" rid="article-103.r28">[28]</xref><xref ref-type="bibr" rid="article-103.r29">[29]</xref><xref ref-type="bibr" rid="article-103.r30">[30]</xref></p>
        <p>Nebivolol is contraindicated in severe bradycardia, cardiogenic shock, decompensated heart failure, second or&#x000a0;third-degree heart block,&#x000a0;severe hepatic impairment, and sick sinus syndrome. However, it is still useful if a functioning pacemaker is present.<xref ref-type="bibr" rid="article-103.r31">[31]</xref></p>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <p>Other disease-related/age group-related relative contraindications include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Bronchospastic disease: &#x003b2;-blockers are not recommended in patients with bronchospastic disease.</p>
          </list-item>
          <list-item>
            <p>Diabetes: Nebivolol may enhance hypoglycemia and mask signs and symptoms (eg, tachycardia) of hypoglycemia.</p>
          </list-item>
          <list-item>
            <p>Hepatic impairment:&#x000a0;Nebivolol&#x000a0;is contraindicated in patients with Child-Pugh Class C hepatic impairment.</p>
          </list-item>
          <list-item>
            <p>Myasthenia gravis: Nebivolol should be used cautiously in patients with myasthenia gravis.</p>
          </list-item>
          <list-item>
            <p>Peripheral vascular disease (PVD) and Raynaud disease: Nebivolol can precipitate the symptoms of arterial insufficiency.</p>
          </list-item>
          <list-item>
            <p>Pheochromocytoma (not on treatment): The patient should be&#x000a0;administered &#x003b1;-blockers before any &#x003b2;-blockers.</p>
          </list-item>
          <list-item>
            <p>Psoriasis: &#x003b2;-blockers can induce or exacerbate psoriasis, but the cause and effect remain unestablished. The proposed mechanism indicates that &#x003b2;-blockers cause intracellular changes in calcium,&#x000a0;affecting&#x000a0;keratinocyte and granulocyte function&#x000a0;by reducing cyclic adenosine monophosphate (cAMP) levels.<xref ref-type="bibr" rid="article-103.r26">[26]</xref></p>
          </list-item>
          <list-item>
            <p>Renal impairment: Dose adjustment is necessary with severe renal impairment (CrCl &#x0003c;30 mL/min).</p>
          </list-item>
          <list-item>
            <p>Thyroid disease: Nebivolol may mask signs and symptoms of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, careful management and monitoring are required. Abrupt withdrawal may worsen symptoms of hyperthyroidism or precipitate thyroid storm.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Pregnancy: Category C medication; it is unclear if nebivolol gets excreted in breast milk; &#x003b2;-blockers can cause serious adverse&#x000a0;effects in nursing infants (eg, bradycardia).</p>
          </list-item>
          <list-item>
            <p>Older&#x000a0;population: Increased frequency of bradycardia in patients aged 65 or older; dose reduction should be considered.</p>
          </list-item>
          <list-item>
            <p>Surgery: Per ACC/AHA guidelines, patients with hypertension and a history of chronic&#x000a0;&#x003b2;-blocker use who are preparing for major surgery should continue their &#x003b2;-blocker regimen. However, initiating &#x003b2;-blockers the day of surgery is not recommended for patients who have not previously used them.<xref ref-type="bibr" rid="article-103.r4">[4]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-103.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Parameters that should be monitored include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Blood pressure</p>
          </list-item>
          <list-item>
            <p>EKG for possible bradycardia</p>
          </list-item>
          <list-item>
            <p>Serum glucose in patients with diabetes mellitus&#x000a0;<xref ref-type="bibr" rid="article-103.r31">[31]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-103.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Clinical presentations of nebivolol overdose usually include bradycardia&#x000a0;and hypotension. Further adverse effects linked to excessive nebivolol intake can cause&#x000a0;vomiting,&#x000a0;heart failure, bronchospasm, and&#x000a0;AV&#x000a0;block.</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>Glucagon is the first-line treatment for &#x003b2;-blocker overdose. Glucagon is only effective for a short time, and prolonged use can cause tachyphylaxis,&#x000a0;rendering&#x000a0;therapy ineffective. Glucagon is administered intravenously (IV) as a slow bolus followed by a continuous infusion. The initial bolus dose is typically 5 mg administered over&#x000a0;1 minute. Constant&#x000a0;heart rate and blood pressure monitoring are required. If&#x000a0;these measures do not increase after 15 minutes, administer another bolus. Glucagon starts working within 3 minutes, with a peak response at 5&#x000a0;to 7 minutes. If there is no notable effect within 10 minutes&#x000a0;of the&#x000a0;second bolus, then it is doubtful that an infusion would benefit the patient. If there is an increase in heart rate and blood pressure, an infusion will be beneficial. The infusion rate should be&#x000a0;between 2 to 5 mg/h. The goal is a mean arterial pressure (MAP) of 60 mm Hg. If a MAP of 60 mm Hg cannot be achieved, the patient&#x000a0;may require additional therapies.<xref ref-type="bibr" rid="article-103.r32">[32]</xref><xref ref-type="bibr" rid="article-103.r33">[33]</xref>&#x000a0;</p>
        <p>Supportive care is required in overdose. Intravenous atropine administration&#x000a0;may be&#x000a0;required to manage bradycardia. Transthoracic or transvenous pacemaker placement may be necessary for heart block (second or third-degree). Intravenous fluids should be administered for hypotension, while inhaled &#x003b2;-2 agonists are indicated for bronchospasm. Intravenous glucose is advised for managing hypoglycemia.&#x000a0;</p>
        <p>Treating anaphylaxis in the setting of &#x003b2;-blocker administration&#x000a0;can be challenging. If epinephrine is ineffective, then glucagon&#x000a0;should be administered as&#x000a0;it can reverse refractory hypotension and bronchospasm during anaphylaxis in patients on &#x003b2;-blockers. Glucagon works by activating adenyl cyclase directly.<xref ref-type="bibr" rid="article-103.r34">[34]</xref></p>
      </sec>
      <sec id="article-103.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Nebivolol is a&#x000a0;medication that is FDA-approved to treat hypertension. All interprofessional healthcare team members must be aware of the&#x000a0;current indications, interactions, adverse effects, and other pharmacodynamics and pharmacokinetic factors that can affect successful therapy implementation and improve patient outcomes.<xref ref-type="bibr" rid="article-103.r12">[12]</xref><xref ref-type="bibr" rid="article-103.r35">[35]</xref>&#x000a0;Cardiologists treat refractory hypertension and complications associated with therapy. Pharmacists review the appropriateness of the selected drug and the dose, look for interactions or other contraindications, and consult the prescriber as necessary. They also counsel patients and their families about appropriate use and&#x000a0;adverse effects. Nurses monitor vital signs, counsel the patient on dosing and administration, monitor for potential adverse effects, and report issues to the team for therapy adjustment. In an overdose of nebivolol, critical care&#x000a0;input is crucial. A medical toxicologist should be consulted as the direct care provided by these specialists has been shown to reduce the length of stay and decrease healthcare utilization.<xref ref-type="bibr" rid="article-103.r36">[36]</xref></p>
        <p>If an overdose is intentional, a psychiatric consultation should be obtained. Nebivolol therapy has its best chance for therapeutic success with minimal adverse events if the interprofessional teamwork&#x000a0;between MDs, DOs, PAs, NPs, and pharmacists is in place.&#x000a0;The 2017 ACC/AHA guidelines for hypertension recommend interprofessional team-based care,&#x000a0;which involves&#x000a0;primary care providers, patients, cardiologists,&#x000a0;physician assistants, nurses, pharmacists, dietitians, community health workers, and social workers.&#x000a0;Randomized controlled trials&#x000a0;and meta-analyses of interprofessional team-based hypertension care involving nurse or pharmacist-led lead intervention have demonstrated optimal blood pressure control compared&#x000a0;to routine care.<xref ref-type="bibr" rid="article-103.r37">[37]</xref><xref ref-type="bibr" rid="article-103.r38">[38]</xref><xref ref-type="bibr" rid="article-103.r39">[39]</xref></p>
      </sec>
      <sec id="article-103.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=103&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=103">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/103/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=103">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-103.s11">
        <title>References</title>
        <ref id="article-103.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiysonge</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Bradley</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Volmink</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mayosi</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Opie</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>Beta-blockers for hypertension.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2017</year>
            <month>Jan</month>
            <day>20</day>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>CD002003</fpage>
            <pub-id pub-id-type="pmid">28107561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <chapter-title>Beta Adrenergic Blocking Agents</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>6</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">31643457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paulison</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>L&#x000e9;os</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Potential cardiotoxic reaction involving rivastigmine and beta-blockers: a case report and review of the literature.</article-title>
            <source>Cardiovasc Toxicol</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>306</fpage>
            <page-range>306-10</page-range>
            <pub-id pub-id-type="pmid">20865460</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Dennison Himmelfarb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DePalma</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jamerson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>MacLaughlin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ovbiagele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Stafford</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>Hypertension</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>71</volume>
            <issue>6</issue>
            <fpage>e13</fpage>
            <page-range>e13-e115</page-range>
            <pub-id pub-id-type="pmid">29133356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Sander</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <article-title>Nebivolol/valsartan combination for the treatment of hypertension: a review.</article-title>
            <source>Future Cardiol</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>573</fpage>
            <page-range>573-583</page-range>
            <pub-id pub-id-type="pmid">33064027</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Authors/Task Force Members:</collab>
              <name>
                <surname>McDonagh</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Metra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Adamo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Baumbach</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>B&#x000f6;hm</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Burri</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>&#x0010c;elutkien&#x00117;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chioncel</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Cleland</surname>
                <given-names>JGF</given-names>
              </name>
              <name>
                <surname>Coats</surname>
                <given-names>AJS</given-names>
              </name>
              <name>
                <surname>Crespo-Leiro</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Farmakis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gilard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Heymans</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hoes</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Jaarsma</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jankowska</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Lainscak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>CSP</given-names>
              </name>
              <name>
                <surname>Lyon</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJV</given-names>
              </name>
              <name>
                <surname>Mebazaa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mindham</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Muneretto</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Francesco Piepoli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rosano</surname>
                <given-names>GMC</given-names>
              </name>
              <name>
                <surname>Ruschitzka</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kathrine Skibelund</surname>
                <given-names>A</given-names>
              </name>
              <collab>ESC Scientific Document Group</collab>
            </person-group>
            <article-title>2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC.</article-title>
            <source>Eur J Heart Fail</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>4</fpage>
            <page-range>4-131</page-range>
            <pub-id pub-id-type="pmid">35083827</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marchini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pompei</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>D'Aniello</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Marrone</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Caglioni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Biscaglia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Campo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tebaldi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Shedding Light on Treatment Options for Coronary Vasomotor Disorders: A Systematic Review.</article-title>
            <source>Cardiovasc Drugs Ther</source>
            <year>2024</year>
            <month>Feb</month>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>151</fpage>
            <page-range>151-161</page-range>
            <pub-id pub-id-type="pmid">35678926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cannata</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stefanini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Carlo-Stella</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chiarito</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Figliozzi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Novelli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lisi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bombace</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Panico</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cosco</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Corrado</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Masci</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mazza</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ricci</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Monti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ferrante</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Santoro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Francone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>da Costa</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>J&#x000fc;ni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Condorelli</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Nebivolol versus placebo in patients undergoing anthracyclines (CONTROL Trial): rationale and study design.</article-title>
            <source>J Cardiovasc Med (Hagerstown)</source>
            <year>2023</year>
            <month>Jul</month>
            <day>01</day>
            <volume>24</volume>
            <issue>7</issue>
            <fpage>469</fpage>
            <page-range>469-474</page-range>
            <pub-id pub-id-type="pmid">37285278</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaya</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Ozkan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gunebakmaz</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Akkaya</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kaya</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Akpek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kalay</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dikilitas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yarlioglues</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Karaca</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Berk</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ardic</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ergin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>YY</given-names>
              </name>
            </person-group>
            <article-title>Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study.</article-title>
            <source>Int J Cardiol</source>
            <year>2013</year>
            <month>Sep</month>
            <day>01</day>
            <volume>167</volume>
            <issue>5</issue>
            <fpage>2306</fpage>
            <page-range>2306-10</page-range>
            <pub-id pub-id-type="pmid">22727976</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mir</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Badi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bugazia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nourelden</surname>
                <given-names>AZ</given-names>
              </name>
              <name>
                <surname>Fathallah</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Ragab</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Alsillak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Elsayed</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Hagrass</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Bawek</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kalot</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brumberger</surname>
                <given-names>ZL</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of cardioprotective drugs in chemotherapy-induced cardiotoxicity: an updated systematic review &#x00026; network meta-analysis.</article-title>
            <source>Cardiooncology</source>
            <year>2023</year>
            <month>Feb</month>
            <day>18</day>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>10</fpage>
            <pub-id pub-id-type="pmid">36804940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weiss</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Nebivolol: novel beta-blocker with nitric oxide-induced vasodilation.</article-title>
            <source>Future Cardiol</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-16</page-range>
            <pub-id pub-id-type="pmid">19804126</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x000c5;gesen</surname>
                <given-names>FN</given-names>
              </name>
              <name>
                <surname>Weeke</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Tfelt-Hansen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tfelt-Hansen</surname>
                <given-names>J</given-names>
              </name>
              <collab>for ESCAPE&#x02010;NET</collab>
            </person-group>
            <article-title>Pharmacokinetic variability of beta-adrenergic blocking agents used in cardiology.</article-title>
            <source>Pharmacol Res Perspect</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>e00496</fpage>
            <pub-id pub-id-type="pmid">31338197</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olawi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kr&#x000fc;ger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grimm</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Infanger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wehland</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Nebivolol in the treatment of arterial hypertension.</article-title>
            <source>Basic Clin Pharmacol Toxicol</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>125</volume>
            <issue>3</issue>
            <fpage>189</fpage>
            <page-range>189-201</page-range>
            <pub-id pub-id-type="pmid">31066991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McNeely</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Goa</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Nebivolol in the management of essential hypertension: a review.</article-title>
            <source>Drugs</source>
            <year>1999</year>
            <month>Apr</month>
            <volume>57</volume>
            <issue>4</issue>
            <fpage>633</fpage>
            <page-range>633-51</page-range>
            <pub-id pub-id-type="pmid">10235696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fongemie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Felix-Getzik</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>A Review of Nebivolol Pharmacology and Clinical Evidence.</article-title>
            <source>Drugs</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>75</volume>
            <issue>12</issue>
            <fpage>1349</fpage>
            <page-range>1349-71</page-range>
            <pub-id pub-id-type="pmid">26177892</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>AlHabeeb</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Mrabeti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Abdelsalam</surname>
                <given-names>AAI</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic Properties of Highly Selective &#x003b2;-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease.</article-title>
            <source>Cardiovasc Drugs Ther</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>36</volume>
            <issue>5</issue>
            <fpage>959</fpage>
            <page-range>959-971</page-range>
            <pub-id pub-id-type="pmid">34106365</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prins</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Neill</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Tyler</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Eckman</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Duval</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Effects of Beta-Blocker Withdrawal in Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis.</article-title>
            <source>JACC Heart Fail</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>3</volume>
            <issue>8</issue>
            <fpage>647</fpage>
            <page-range>647-53</page-range>
            <pub-id pub-id-type="pmid">26251094</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Regitz-Zagrosek</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Roos-Hesselink</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Bauersachs</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Blomstr&#x000f6;m-Lundqvist</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>C&#x000ed;fkov&#x000e1;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>De Bonis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iung</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Kintscher</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kranke</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Morais</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pieper</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Presbitero</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rosano</surname>
                <given-names>GMC</given-names>
              </name>
              <name>
                <surname>Seeland</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Simoncini</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Swan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Warnes</surname>
                <given-names>CA</given-names>
              </name>
              <collab>ESC Scientific Document Group</collab>
            </person-group>
            <article-title>2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.</article-title>
            <source>Eur Heart J</source>
            <year>2018</year>
            <month>Sep</month>
            <day>07</day>
            <volume>39</volume>
            <issue>34</issue>
            <fpage>3165</fpage>
            <page-range>3165-3241</page-range>
            <pub-id pub-id-type="pmid">30165544</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r19">
          <label>19</label>
          <element-citation publication-type="book">
            <chapter-title>Nebivolol</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>5</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">30000861</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <article-title>Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222.</article-title>
            <source>Obstet Gynecol</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>135</volume>
            <issue>6</issue>
            <fpage>e237</fpage>
            <page-range>e237-e260</page-range>
            <pub-id pub-id-type="pmid">32443079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flather</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Shibata</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Coats</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Van Veldhuisen</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Parkhomenko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Borbola</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cohen-Solal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dumitrascu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lechat</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Soler-Soler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tavazzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Spinarova</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Toman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>B&#x000f6;hm</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Anker</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Poole-Wilson</surname>
                <given-names>PA</given-names>
              </name>
              <collab>SENIORS Investigators</collab>
            </person-group>
            <article-title>Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).</article-title>
            <source>Eur Heart J</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>215</fpage>
            <page-range>215-25</page-range>
            <pub-id pub-id-type="pmid">15642700</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cicero</surname>
                <given-names>AFG</given-names>
              </name>
              <name>
                <surname>Kuwabara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Borghi</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>A Critical Review of Nebivolol and its Fixed-Dose Combinations in the Treatment of Hypertension.</article-title>
            <source>Drugs</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>78</volume>
            <issue>17</issue>
            <fpage>1783</fpage>
            <page-range>1783-1790</page-range>
            <pub-id pub-id-type="pmid">30426333</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ha</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Migraine Headache Prophylaxis.</article-title>
            <source>Am Fam Physician</source>
            <year>2019</year>
            <month>Jan</month>
            <day>01</day>
            <volume>99</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-24</page-range>
            <pub-id pub-id-type="pmid">30600979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mangrella</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fici</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Pharmacology of nebivolol.</article-title>
            <source>Pharmacol Res</source>
            <year>1998</year>
            <month>Dec</month>
            <volume>38</volume>
            <issue>6</issue>
            <fpage>419</fpage>
            <page-range>419-31</page-range>
            <pub-id pub-id-type="pmid">9990650</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lou</surname>
                <given-names>IX</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>Relationship Between Hypertension, Antihypertensive Drugs and Sexual Dysfunction in Men and Women: A Literature Review.</article-title>
            <source>Vasc Health Risk Manag</source>
            <year>2023</year>
            <volume>19</volume>
            <fpage>691</fpage>
            <page-range>691-705</page-range>
            <pub-id pub-id-type="pmid">37941540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Awad</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Sakhamuru</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kambampati</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wasim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Malik</surname>
                <given-names>BH</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of Beta-Blocker Induced Psoriasis, and Psoriasis De Novo at the Cellular Level.</article-title>
            <source>Cureus</source>
            <year>2020</year>
            <month>Jul</month>
            <day>02</day>
            <volume>12</volume>
            <issue>7</issue>
            <fpage>e8964</fpage>
            <pub-id pub-id-type="pmid">32766006</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saedder</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Thomsen</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Hasselstr&#x000f8;m</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Jornil</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Heart insufficiency after combination of verapamil and metoprolol: A fatal case report and literature review.</article-title>
            <source>Clin Case Rep</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>7</volume>
            <issue>11</issue>
            <fpage>2042</fpage>
            <page-range>2042-2048</page-range>
            <pub-id pub-id-type="pmid">31788248</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ong</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Ong</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Kow</surname>
                <given-names>FP</given-names>
              </name>
            </person-group>
            <article-title>Beta-blockers for heart failure: an evidence based review answering practical therapeutic questions.</article-title>
            <source>Med J Malaysia</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>67</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-11</page-range>
            <pub-id pub-id-type="pmid">22582541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pessina</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Metabolic effects and safety profile of nebivolol.</article-title>
            <source>J Cardiovasc Pharmacol</source>
            <year>2001</year>
            <month>Dec</month>
            <volume>38 Suppl 3</volume>
            <fpage>S33</fpage>
            <page-range>S33-5</page-range>
            <pub-id pub-id-type="pmid">11811391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <article-title>[Heart and lung disease. Are beta blockers allowed in asthma?].</article-title>
            <source>MMW Fortschr Med</source>
            <year>2001</year>
            <month>May</month>
            <day>24</day>
            <volume>143</volume>
            <issue>21</issue>
            <fpage>58</fpage>
            <pub-id pub-id-type="pmid">11420835</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheng</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Nebivolol: a third-generation beta-blocker for hypertension.</article-title>
            <source>Clin Ther</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>447</fpage>
            <page-range>447-62</page-range>
            <pub-id pub-id-type="pmid">19393838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zaritsky</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Horowitz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chernow</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Glucagon antagonism of calcium channel blocker-induced myocardial dysfunction.</article-title>
            <source>Crit Care Med</source>
            <year>1988</year>
            <month>Mar</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>246</fpage>
            <page-range>246-51</page-range>
            <pub-id pub-id-type="pmid">3277781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heinroth</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Kuhn</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Walper</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Busch</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Winkler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Prondzinsky</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>[Acute beta 1-selective beta-receptor blocker nebivolol poisoning in attempted suicide].</article-title>
            <source>Dtsch Med Wochenschr</source>
            <year>1999</year>
            <month>Oct</month>
            <day>22</day>
            <volume>124</volume>
            <issue>42</issue>
            <fpage>1230</fpage>
            <page-range>1230-4</page-range>
            <pub-id pub-id-type="pmid">10572531</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murakami</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kaneko</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yokoyama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ishizaki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sekino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Murata</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hara</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Successful treatment of severe adrenaline-resistant anaphylactic shock with glucagon in a patient taking a beta-blocker: a case report.</article-title>
            <source>JA Clin Rep</source>
            <year>2021</year>
            <month>Dec</month>
            <day>15</day>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>86</fpage>
            <pub-id pub-id-type="pmid">34907487</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bouhanick</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Blacher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Huyghe</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Colson</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Boivin</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Mounier-Vehier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Denolle</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fauvel</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>[Sexual dysfunction and antihypertensive treatment: Involvement of the different therapeutic classes and what to do about the treatment of hypertension].</article-title>
            <source>Presse Med</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>48</volume>
            <issue>11 Pt 1</issue>
            <fpage>1222</fpage>
            <page-range>1222-1228</page-range>
            <pub-id pub-id-type="pmid">31303372</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>King</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Danagoulian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Menke</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Saul</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abesamis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pizon</surname>
                <given-names>AF</given-names>
              </name>
            </person-group>
            <article-title>The Effect of a Medical Toxicology Inpatient Service in an Academic Tertiary Care Referral Center.</article-title>
            <source>J Med Toxicol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>12</fpage>
            <page-range>12-21</page-range>
            <pub-id pub-id-type="pmid">30353414</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carter</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Daly</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>The potency of team-based care interventions for hypertension: a meta-analysis.</article-title>
            <source>Arch Intern Med</source>
            <year>2009</year>
            <month>Oct</month>
            <day>26</day>
            <volume>169</volume>
            <issue>19</issue>
            <fpage>1748</fpage>
            <page-range>1748-55</page-range>
            <pub-id pub-id-type="pmid">19858431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clark</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Nurse led interventions to improve control of blood pressure in people with hypertension: systematic review and meta-analysis.</article-title>
            <source>BMJ</source>
            <year>2010</year>
            <month>Aug</month>
            <day>23</day>
            <volume>341</volume>
            <fpage>c3995</fpage>
            <pub-id pub-id-type="pmid">20732968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-103.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santschi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Chiolero</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Colosimo</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Platt</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Taff&#x000e9;</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Burnier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Burnand</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Paradis</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Improving blood pressure control through pharmacist interventions: a meta-analysis of randomized controlled trials.</article-title>
            <source>J Am Heart Assoc</source>
            <year>2014</year>
            <month>Apr</month>
            <day>10</day>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>e000718</fpage>
            <pub-id pub-id-type="pmid">24721801</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
